Please login to the form below

Not currently logged in

New Boehringer Ingelheim facility in US

Germany-based pharmaceutical company Boehringer Ingelheim has started the construction of a new safety assessment building in the US

Boehringer Ingelheim, the German pharmaceutical company, has started building a $42.5m safety assessment facility at its campus in Danbury-Ridgefield, Connecticut, in the US.

Dr James Baxter, Boehringer Ingelheim's senior vice president for development in the US, said the 63,000sq ft building would provide a safety testing facility for the new biologic drugs that the company is developing in Connecticut and at its facilities in Laval, Canada; Vienna, Austria and Biberach, Germany. It hopes to open the new building in 2013.

The company is also proposing to build a $65m pilot plant replacement facility nearby, to synthesise and produce the active ingredients it needs for future new drugs. It has not yet secured permission to build the second facility.

However, the company has been offered seven-year tax abatement to stay in the area and when the building is finished, Boehringer Ingelheim will only pay 15 per cent of the taxes assessed on the building for seven years. After this period, it will pay full tax.

24th August 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked